中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2015年
7期
37-38
,共2页
张艳清%王叨%秦好奇%柴方圆%刘玉峰
張豔清%王叨%秦好奇%柴方圓%劉玉峰
장염청%왕도%진호기%시방원%류옥봉
白血病%淋巴细胞%无病生存%临床路径%疗效
白血病%淋巴細胞%無病生存%臨床路徑%療效
백혈병%림파세포%무병생존%림상로경%료효
Leukemia%Lymphoblastic%Disease-free survival%Clinical pathway%Efficacy
目的 回顾性比较分析两种不同治疗方案治疗194例初治儿童急性淋巴细胞白血病(ALL)患儿的疗效.方法 选择2010年6月1日至2013年12月31日于郑州大学第一附属医院小儿内科初诊ALL患儿194例,其中135例采用《儿童急性淋巴细胞白血病临床路径(2010年版)》治疗方案(简称“临床路径组”),59例采用《儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)-2006年》治疗方案(简称“06方案组”),对患儿的临床资料、早期疗效、复发率、3年无病生存率进行分析比较.结果 194例ALL患儿低危型135例,中危型59例;诱导治疗第8天泼尼松实验均反应良好,诱导治疗第15天骨髓完全缓解率(CR)为92.8％,第33天CR率为100％;临床路径组ALL患儿低危型、中危型复发率分别为11.39％ (9/79)、14.28％(8/56),06方案组低危型、中危型复发率为9.09％(3/33)、11.54％(3/26);对于低危型ALL患儿,06方案组的3年无事件生存率(88.7％)稍高于临床路径组(87.2％),但差异未见统计学意义(P＞0.05);对于中危型ALL患儿,06方案组的3年无事件生存率(85.4％)高于临床路径组(78.2％),但差异亦未见统计学意义(P＞0.05).结论 两种方案治疗儿童ALL的疗效差异未见统计学意义.
目的 迴顧性比較分析兩種不同治療方案治療194例初治兒童急性淋巴細胞白血病(ALL)患兒的療效.方法 選擇2010年6月1日至2013年12月31日于鄭州大學第一附屬醫院小兒內科初診ALL患兒194例,其中135例採用《兒童急性淋巴細胞白血病臨床路徑(2010年版)》治療方案(簡稱“臨床路徑組”),59例採用《兒童急性淋巴細胞白血病診療建議(第三次脩訂草案)-2006年》治療方案(簡稱“06方案組”),對患兒的臨床資料、早期療效、複髮率、3年無病生存率進行分析比較.結果 194例ALL患兒低危型135例,中危型59例;誘導治療第8天潑尼鬆實驗均反應良好,誘導治療第15天骨髓完全緩解率(CR)為92.8％,第33天CR率為100％;臨床路徑組ALL患兒低危型、中危型複髮率分彆為11.39％ (9/79)、14.28％(8/56),06方案組低危型、中危型複髮率為9.09％(3/33)、11.54％(3/26);對于低危型ALL患兒,06方案組的3年無事件生存率(88.7％)稍高于臨床路徑組(87.2％),但差異未見統計學意義(P＞0.05);對于中危型ALL患兒,06方案組的3年無事件生存率(85.4％)高于臨床路徑組(78.2％),但差異亦未見統計學意義(P＞0.05).結論 兩種方案治療兒童ALL的療效差異未見統計學意義.
목적 회고성비교분석량충불동치료방안치료194례초치인동급성림파세포백혈병(ALL)환인적료효.방법 선택2010년6월1일지2013년12월31일우정주대학제일부속의원소인내과초진ALL환인194례,기중135례채용《인동급성림파세포백혈병림상로경(2010년판)》치료방안(간칭“림상로경조”),59례채용《인동급성림파세포백혈병진료건의(제삼차수정초안)-2006년》치료방안(간칭“06방안조”),대환인적림상자료、조기료효、복발솔、3년무병생존솔진행분석비교.결과 194례ALL환인저위형135례,중위형59례;유도치료제8천발니송실험균반응량호,유도치료제15천골수완전완해솔(CR)위92.8％,제33천CR솔위100％;림상로경조ALL환인저위형、중위형복발솔분별위11.39％ (9/79)、14.28％(8/56),06방안조저위형、중위형복발솔위9.09％(3/33)、11.54％(3/26);대우저위형ALL환인,06방안조적3년무사건생존솔(88.7％)초고우림상로경조(87.2％),단차이미견통계학의의(P＞0.05);대우중위형ALL환인,06방안조적3년무사건생존솔(85.4％)고우림상로경조(78.2％),단차이역미견통계학의의(P＞0.05).결론 량충방안치료인동ALL적료효차이미견통계학의의.
Objective To retrospectively analyze the effects of two different treatment regimens on 194 cases of newly diagnosed childhood acute lymphoblastic leukemia(ALL).Methods The 194 cases of children with newly diagnosed all from June 1,2010 to December 31,2013 in pediatrics ward of the first affiliated hospital of Zhengzhou university,135 cases used the " clinical pathway of childhood acute lymphoblastic leukemia (2010 edition)" treatment program (referred to as " clinical pathway group"),while 59 cases used the " treatment recommendations of childhood acute lymphoblastic leukemia (the third Amendment Bill)-2006" treatment regimens (referred to as "06 program group")[1].The clinical data,early efficacy,relapse rate,three-year disease-free survival rates of all the ALL patients were analyzed and compared.Results Among the 194 paitents,135 were l9w-risk(LR),59 were medium-risk (MR).All the patients were prednisone good response ALL group in Prednisone test on day 8 th.The CR rate on day 15 was 92.8％ and 100％ on day 33.The reoccur rate of clinical pathway group was 1 1.39％ (9/79) for LR,and 14.28％ (8/56) for MR.While the 06 program group was 9.09％ (3/33) for LR,and 11.54％ (3/26) for MR.For low-risk ALL patients,the 3-year diseasefree survival rate of 06 program group was 88.7％,which was slightly higher than that of the clinical pathway group (87.2％,P ＞ 0.05),but the difference was not statistically significant;for medium-risk ALL patients,the 3-year disease-free survival rate of 06 program group was 85.4％,which was higher than that of the clinical pathway group (78.2％,P ＞0.05),but the difference was also no statistically significant.Conclusions The two regimens have no significant difference in the efficacy on childhood ALL.
